Available clinical trials for mild cognitive impairment

REACH Clinical Trial

The REACH clinical trial is 1 of 16 trials worldwide offering promising therapies for Alzheimer’s disease and dementia funded by the Alzheimer’s Association’s Part the Cloud global research grant program and Bill Gates.
The trial will evaluate the use of Rapamycin to slow progression of amnestic mild cognitive impairment and early-stage Alzheimer’s. It will also collect vital information on Alzheimer’s markers and relevant outcomes for future clinical trials.

Eligibility: Adults, ages 55 to 89, diagnosed with mild cognitive impairment or Alzheimer’s disease

CARPE DIEM Study: Cognition, Age and Rapamycin Effectiveness-Downregulation of the mTor Pathway

The purpose of this study is to evaluate if if the drug, Rapamycin, will reach the brain and effectively treat symptoms of Alzheimer’s disease and mild cognitive impairment using cerebrospinal fluid.

Eligibility: Adults, ages 55 to 85, diagnosed with mild cognitive impairment or early stages of Alzheimer’s disease

MIND Study: Memory Improvement Through Nicotine Dosing

The purpose of this study is to determine whether nicotine (in patch form) improves memory and functioning in adults diagnosed with mild cognitive impairment (MCI).

Eligibility: Healthy, non-smoking adults, age 55+ who notice changes in their memory or whose family member notice changes.